Zeynep Karakas

Zeynep Karakas

Auto-generated profile, based on publicly available information

Zeynep Karakas

Division of Hematology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, 34452 Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2013 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MEMohsen Elalfy
Mohsen Elalfy
YWYasser Wali
Yasser Wali
MQMohamad Qari
Mohamad Qari
GDGhazi Al Damanhouri
Ghazi Al Damanhouri
YAYoussef Al‐Tonbary
Youssef Al‐Tonbary
FTFernando Tricta
Fernando Tricta

2 September 2020 in Hemoglobin
Verified
Journal Article
Closed access
SKSefika I.K. Karadag
Sefika I.K. Karadag
ZKZeynep Karakas
Zeynep Karakas
Yasin YilmazYasin Yilmaz
Yasin Yilmaz
NGNurdan Gul
Nurdan Gul
ADAli A. Demir
Ali A. Demir
MDMemduh Dursun
Memduh Dursun
The endocrinological complications are a great concern in transfusion-dependent β-thalassemia (β-thal) patients. The pituitary iron deposition is regarded as the main cause of hormonal changes in thalassemic patients. In this study, our aim was to explore the association between endocrinological complications and pituitary iron overload by magnetic resonance imaging (MRI). Fifty transfusion-dependent thalassemia (TDT) patients were recruited for the study. Pituitary MRIs of patients were taken using a 1.5 Tesla Philips MRI machine. There was at least one clinical endocrine complication in two of three patients. The iron accumulation was moderate in the liver (60.0%) and was mild in hypophysis (16.0%) and in heart (8.0%). The hypogonadism and diabetes mellitus (DM) were not seen with a significantly increased pituitary iron burden. The hypogonadism was related to cardiac iron deposition (p = 0.04). The short stature was associated with a hepatic iron overload (p = 0.05). The conventional follow-up of patients with TDT might be inadequate and screening of patients with MRI of hypophysis along with heart and liver leads to better results.

8 April 2023 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
SFSinem Firtina
Sinem Firtina
YEYucel Erbilgin
Yucel Erbilgin
ÖHÖzden Hatırnaz
Özden Hatırnaz
SKSerap Karaman
Serap Karaman
ZKZeynep Karakas
Zeynep Karakas
MSMuge Sayitoglu
Muge Sayitoglu
The tumor suppressor protein 53 (TP53) gene is one of the most studied genes in cancer. Although TP53 variants are rare events in acute leukemia, recent observations showed that relapse samples might harbor TP53 variants. Here, we aimed to determine TP53 variants (hotspot region, exon 4–11) in childhood acute lymphoblastic leukemia (B and T-ALL) patients (n = 94) including diagnostic-relapse pairs (n = 15) by amplicon sequencing and evaluate the clinical impact of these variants. In total, nine different (E298*, R283C, R273H, L252F, C229F, I195T, E286G, c.955_956insC, and c.920-1G > C) variants were identified in 17 (18%) childhood ALL patients. c.(920-1G> C) splice site variant and c.(955_956insC) insertion were reported for the first time. In diagnose-relapse pair samples, we identified acquired and/or loss of TP53 variants in the samples at the time of relapse. TP53 variants were found to be more common in T-ALL (37%) than in B-ALL patients (9%). Pathogenic TP53 variants were associated with a shorter overall survival time (p = 0.001).TP53 variants were found to be associated with inferior outcomes in our cohort and can be an independent risk factor for poor prognosis in childhood acute leukemia patients. Identification of low-frequent variants with next-generation sequencing approaches enables better knowledge of the clonal dynamics of ALL.

1 August 2019 in Leukemia Research
Verified
Journal Article
Closed access
YEYucel Erbilgin
Yucel Erbilgin
SFSinem Firtina
Sinem Firtina
SMSevcan Mercan
Sevcan Mercan
ÖHÖzden Hatırnaz
Özden Hatırnaz
SKSerap Karaman
Serap Karaman
MSMuge Sayitoglu
Muge Sayitoglu

1 September 2021 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
SOSuheyla Ocak
Suheyla Ocak
SKSerap Karaman
Serap Karaman
SVSema Vural
Sema Vural
GKGonca Keskindemirci
Gonca Keskindemirci
DTDeniz Tugcu
Deniz Tugcu
ZKZeynep Karakas
Zeynep Karakas
Objective: Children with cancer have an increased risk for hepatitis B virus (HBV) infections due to chemotherapy-induced secondary immunodeficiency and frequent blood transfusions. The aim of this study is to evaluate the efficacy and safety of hepatitis B vaccination during the intensive induction chemotherapy in children with cancer found to be seronegative for hepatitis B on admission. Materials and Methods: Children newly diagnosed with cancer were evaluated for the presence of hepatitis B surface antigen (HBsAg) and antibody on admission. The children negative for both were included in the study. A super-accelerated vaccination scheme (3 booster doses at days 1-5, 8-12, and 28-33) was administered to these seronegative children concurrently with induction chemotherapy. Antibody response was checked 4-8 weeks after the last vaccination and 6 months after the end of the treatment. Results: Eleven out of 122 children were seronegative for hepatitis B on admission (9%). Acute lymphoblastic leukemia, lymphoma, and solid tumors were diagnosed in 5, 4, and 2 children, respectively. Complete seroconversion was achieved in 4-8 weeks after the last vaccination with high titers of anti-HBs antibody, and all patients remained antibody-positive until 6 months after the completion of chemotherapy. Conclusion: The risk of transfusion-related infections increases with a number of transfused products and donor exposures, and it is more significant for immunosuppressed children with hematologic and oncologic malignancies. Hepatitis B vaccination could safely be applied with brisk and sustained responses in this vulnerable population, based on the local epidemiological data. Cite this article as: Ocak S, Karaman S, Vural S, et al. Hepatitis B vaccination in children with ongoing cancer treatment: A safety and efficacy study of super-accelerated vaccination scheme. Turk Arch Pediatr. 2021; 56(5): 469-473.

22 December 2024 in Children
Verified
Journal Article
Open access
PDF file
CBCenk Baykan
Cenk Baykan
MÇMelike Mete Çiftseven
Melike Mete Çiftseven
GKGonca Keskindemirci
Gonca Keskindemirci
OAOyku Ozboru Askan
Oyku Ozboru Askan
AKAlev Bakır Kayı
Alev Bakır Kayı
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
Introduction and Aim: Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test. Method: In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023. In total, 40 children (n1) diagnosed with hemangioma who received propranolol treatment and 31 children (n2) who were only under observation were included. A control group of 31 healthy children (n3) matched for age and gender was also included. The demographic, clinical, perinatal, and postnatal characteristics of the total 102 children were recorded from their medical records. Neurodevelopmental levels were assessed with the Bayley-III test. The significance level was set at (p < 0.05). Results: The Bayley-III test composite and percentile scores were used to evaluate the neurodevelopmental levels. Significant differences in motor functions were found between the treated and untreated groups compared to the healthy control group (p = 0.006 and p = 0.006). However, no significant differences were found in cognitive, language, and social-emotional skills. Cognitive, language, and motor functions were associated with maternal education level, and additionally, cognitive functions were also associated with paternal education level. Conclusions: Propranolol has a relatively safer side effect profile, and therefore, it has been described as a safe agent. In our study, no significant effect of propranolol on neurodevelopment was observed. The difference in motor skills shown was mainly between the healthy control group (n3) and the treated and untreated group (n1 and n2), which led to the conclusion that the relevant difference could be due to factors other than propranolol itself.